GSK plc (NYSE: GSK) reports 4.08B total voting rights and treasury shares

Rhea-AI Filing Summary

GSK plc reports its share capital and voting rights position as at 30 November 2025. The company had 4,315,433,684 issued Ordinary Shares of 31 ¼ pence each, of which 236,608,577 Ordinary Shares were held in treasury. After excluding the treasury shares, the total number of voting rights in GSK is 4,078,825,107. Shareholders can use this voting-rights figure to determine whether they need to notify GSK and the UK regulator of any changes in their shareholdings under the applicable transparency rules.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 1 December 2025, London UK

Total Voting Rights

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 30 November 2025 consisted of 4,315,433,684 shares of 31 ¼ pence each ('Ordinary Shares'), of which 236,608,577 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,078,825,107. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

1 December 2025

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: December 01, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What total voting rights did GSK (GSK) report as of 30 November 2025?

As of 30 November 2025, GSK plc reported a total of 4,078,825,107 voting rights. This number is calculated after excluding shares held in treasury and is used by shareholders to assess disclosure obligations under UK transparency rules.

How many GSK (GSK) Ordinary Shares were in issue and how many were held in treasury?

GSK’s issued share capital as at 30 November 2025 consisted of 4,315,433,684 Ordinary Shares of 31 ¼ pence each. Of these, 236,608,577 Ordinary Shares were held in treasury.

Why are GSK’s total voting rights important for shareholders?

The 4,078,825,107 total voting rights figure is the denominator shareholders use to calculate whether their holding in GSK has reached or crossed a threshold that must be notified under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

What regulatory framework applies to GSK’s voting rights disclosure?

The disclosure is made in conformity with the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rule 5.6.1R, which requires issuers to inform the market of changes in total voting rights and capital.

Who signed the GSK (GSK) report on total voting rights?

The report was signed on behalf of GSK plc by Victoria Whyte, who is identified as Company Secretary and authorised signatory.

How can investors contact GSK regarding shareholding notifications?

Notifications and related communications regarding shareholdings in GSK plc may be sent by email to company.secretary@gsk.com, as indicated in the disclosure.